← Back to screener

IDEAYA Biosciences, Inc. IDYA

Rank #2316 · Nasdaq · $2.8B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
24.7
P/E
-24.9
P/B
8.04
ROE
-32.3%
Op. Margin
-574.9%
Debt Ratio
19%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -24.9x, P/B 8.04x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -32.3%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 19%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 54.1% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019–$-0.0B$-0.0B$-0.0B–-172
2020$0.0B$-0.0B$-0.0B$-0.0B-186.4-80
2021$0.0B$-0.0B$-0.0B$-0.0B–-204
2022$0.0B$-0.0B$-0.0B$0.1B-180.980
2023$0.0B$-0.1B$-0.0B$0.2B-179.919
2024$0.1B$-0.1B$-0.1B$0.3B-122.79
2025$0.0B$-0.1B$-0.1B$0.3B-574.919

← See the full screener